Eleni Venetsanakos

849 total citations
19 papers, 708 citations indexed

About

Eleni Venetsanakos is a scholar working on Molecular Biology, Oncology and Biotechnology. According to data from OpenAlex, Eleni Venetsanakos has authored 19 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Oncology and 3 papers in Biotechnology. Recurrent topics in Eleni Venetsanakos's work include Melanoma and MAPK Pathways (5 papers), Fibroblast Growth Factor Research (4 papers) and Cancer Research and Treatments (3 papers). Eleni Venetsanakos is often cited by papers focused on Melanoma and MAPK Pathways (5 papers), Fibroblast Growth Factor Research (4 papers) and Cancer Research and Treatments (3 papers). Eleni Venetsanakos collaborates with scholars based in United States, Australia and Spain. Eleni Venetsanakos's co-authors include Martin McMahon, Nancy W. Abbey, Don Ganem, Brian Herndier, Jill Bechtel, Michael Lagunoff, Jillian Bradley, Ian Beckman, Thea D. Tlsty and Serguei R. Romanov and has published in prestigious journals such as Journal of Clinical Oncology, Molecular and Cellular Biology and Cancer Research.

In The Last Decade

Eleni Venetsanakos

18 papers receiving 692 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eleni Venetsanakos United States 10 334 321 155 147 72 19 708
Janet L. Maldonado United States 5 438 1.3× 488 1.5× 66 0.4× 99 0.7× 87 1.2× 6 714
Dennis L. Rousseau United States 9 372 1.1× 304 0.9× 125 0.8× 57 0.4× 83 1.2× 14 648
Karl R. N. Baumforth United Kingdom 12 403 1.2× 436 1.4× 73 0.5× 151 1.0× 150 2.1× 19 863
Erich Weber Switzerland 10 396 1.2× 418 1.3× 73 0.5× 174 1.2× 104 1.4× 17 757
Magali Herrant France 10 200 0.6× 637 2.0× 75 0.5× 179 1.2× 95 1.3× 11 883
Shyamal D. Desai United States 13 328 1.0× 654 2.0× 75 0.5× 400 2.7× 104 1.4× 17 935
Dorothy J. Park United States 15 205 0.6× 549 1.7× 58 0.4× 299 2.0× 99 1.4× 22 917
Sandeep Nambiar Germany 14 344 1.0× 674 2.1× 92 0.6× 121 0.8× 218 3.0× 26 948
Huiping Pei United States 10 263 0.8× 606 1.9× 48 0.3× 134 0.9× 114 1.6× 10 774
Erica Riveiro‐Falkenbach Spain 10 192 0.6× 362 1.1× 105 0.7× 94 0.6× 62 0.9× 25 575

Countries citing papers authored by Eleni Venetsanakos

Since Specialization
Citations

This map shows the geographic impact of Eleni Venetsanakos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eleni Venetsanakos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eleni Venetsanakos more than expected).

Fields of papers citing papers by Eleni Venetsanakos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eleni Venetsanakos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eleni Venetsanakos. The network helps show where Eleni Venetsanakos may publish in the future.

Co-authorship network of co-authors of Eleni Venetsanakos

This figure shows the co-authorship network connecting the top 25 collaborators of Eleni Venetsanakos. A scholar is included among the top collaborators of Eleni Venetsanakos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eleni Venetsanakos. Eleni Venetsanakos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Rastogi, Shubhra, et al.. (2025). Preclinical Activity of the Type II RAF Inhibitor Tovorafenib in Tumor Models Harboring Either a BRAF Fusion or an NF1 Loss-of-Function Mutation. Cancer Research Communications. 5(4). 668–679. 3 indexed citations
2.
3.
Rastogi, Shubhra, et al.. (2024). Abstract 1972: Preclinical activity of the type II RAF inhibitor tovorafenib in tumor models harboring either a BRAF fusion or a NF1-LOF mutation. Cancer Research. 84(6_Supplement). 1972–1972. 1 indexed citations
4.
Venetsanakos, Eleni, et al.. (2021). Abstract 1481: DAY101, a potent pan-RAF inhibitor with activity in preclinical models harboring MAPK pathway alterations beyond BRAF V600E mutation. Cancer Research. 81(13_Supplement). 1481–1481. 2 indexed citations
5.
Joseph, James D., Marcos González‐López, Christina K. Galang, et al.. (2018). Abstract 4719: Small-molecule antagonists of the Aryl Hydrocarbon Receptor (AhR) promote activation of human PBMCs in vitro and demonstrate significant impact on tumor growth and immune modulation in vivo. Cancer Research. 78(13_Supplement). 4719–4719. 9 indexed citations
6.
Martin, Leenus, Tzuling Cheng, Dominic I. James, et al.. (2018). Abstract 1943: PARG inhibitors exhibit synthetic lethality with XRCC1 deficiency and a cellular mechanism of action that is distinct from PARP inhibition. Cancer Research. 78(13_Supplement). 1943–1943. 4 indexed citations
7.
Venetsanakos, Eleni, Ken A. Brameld, Vernon T. Phan, et al.. (2017). The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance. Molecular Cancer Therapeutics. 16(12). 2668–2676. 22 indexed citations
8.
Piha‐Paul, Sarina A., Cinta Hierro, Valentina Boni, et al.. (2017). A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.. Journal of Clinical Oncology. 35(15_suppl). TPS2616–TPS2616. 2 indexed citations
9.
10.
Piha‐Paul, Sarina A., Cinta Hierro, Jens Oliver Funk, et al.. (2016). A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors, followed by expansion cohorts in patients with FGFR genetic alterations.. Journal of Clinical Oncology. 34(15_suppl). TPS2602–TPS2602. 3 indexed citations
11.
Aronchik, Ida, B.A. Appleton, Stephen E. Basham, et al.. (2014). Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers. Molecular Cancer Research. 12(5). 803–812. 61 indexed citations
12.
Venetsanakos, Eleni, Darrin D. Stuart, Nguyêñ Duy Tân, et al.. (2006). CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models. Cancer Research. 66. 1140–1140. 10 indexed citations
13.
Lagunoff, Michael, Jill Bechtel, Eleni Venetsanakos, et al.. (2002). De Novo Infection and Serial Transmission of Kaposi's Sarcoma-Associated Herpesvirus in Cultured Endothelial Cells. Journal of Virology. 76(5). 2440–2448. 164 indexed citations
14.
Venetsanakos, Eleni, Amer M. Mirza, Christie Fanton, et al.. (2002). Induction of Tubulogenesis in Telomerase-Immortalized Human Microvascular Endothelial Cells by Glioblastoma Cells. Experimental Cell Research. 273(1). 21–33. 96 indexed citations
15.
Woods, Douglas, Holly Cherwinski, Eleni Venetsanakos, et al.. (2001). Induction of β3-Integrin Gene Expression by Sustained Activation of the Ras-Regulated Raf–MEK–Extracellular Signal-Regulated Kinase Signaling Pathway. Molecular and Cellular Biology. 21(9). 3192–3205. 108 indexed citations
16.
Caminschi, Irina, Eleni Venetsanakos, Clement C. Leong, et al.. (1999). Cytokine Gene Therapy of Mesothelioma: Immune and Antitumor Effects of Transfected Interleukin-12. American Journal of Respiratory Cell and Molecular Biology. 21(3). 347–356. 27 indexed citations
17.
Caminschi, Irina, et al.. (1999). Cytokine Gene Therapy of Mesothelioma. UWA Profiles and Research Repository (University of Western Australia). 21(3). 347–356. 1 indexed citations
18.
Caminschi, Irina, Eleni Venetsanakos, Clement C. Leong, et al.. (1998). Interleukin-12 Induces an Effective Antitumor Response in Malignant Mesothelioma. American Journal of Respiratory Cell and Molecular Biology. 19(5). 738–746. 38 indexed citations
19.
Venetsanakos, Eleni, et al.. (1997). High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. British Journal of Cancer. 75(12). 1826–1830. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janet L. Maldonado Breakdown of academic impact, for papers by Dennis L. Rousseau Breakdown of academic impact, for papers by Karl R. N. Baumforth Breakdown of academic impact, for papers by Erich Weber Breakdown of academic impact, for papers by Magali Herrant Breakdown of academic impact, for papers by Shyamal D. Desai Breakdown of academic impact, for papers by Dorothy J. Park Breakdown of academic impact, for papers by Sandeep Nambiar Breakdown of academic impact, for papers by Huiping Pei Breakdown of academic impact, for papers by Erica Riveiro‐Falkenbach
Rankless by CCL
2026